International Hepatology

At the 2025 World Hepatitis Day Campaign Conference and the 7th Academic Conference on Clinical Cure of Chronic Hepatitis B, hosted by the China Foundation for Hepatitis Prevention and Control, Professor George Lau, Chairman of Hong Kong’s Humanity Medical Group and Chief Physician at Zhongshan Hospital affiliated with Fudan University, shared insights on the most cost-effective strategies for HBV antiviral therapy from an economic perspective. Hepatology Digest invited Prof. George Lau for an in-depth interview on the current status of hepatitis B prevention and treatment as well as economic evaluation.

At the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025), Professor George Lau, Chairman of Hong Kong Humanity Medical Group and Director of Humanity Medical Clinical Research Center, shared important insights on cuttingedge topics including clinical cure of chronic hepatitis B (CHB) and liver cancer prevention. With the WHO’s 2030 goal to eliminate CHB approaching, China’s CHB prevention and treatment efforts face new opportunities and challenges. In this exclusive interview, drawing on his extensive clinical experience, Professor Lau systematically outlines key breakthroughs and remaining dilemmas in the fields of CHB clinical cure and liver cancer prevention, offering valuable professional perspectives to advance China’s work in CHB and liver cancer control.

Led by Dr. Jianhong Zhong of Guangxi Medical University Cancer Hospital, the GUIDANCE003 study presents compelling evidence that hepatectomy significantly improves survival in patients with initially unresectable hepatocellular carcinoma (HCC)…

Editor’s Note: The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), themed “Standardized Diagnosis and Treatment, Innovation-Driven Progress,” will be held from September 10–14, 2025, in Jinan,…

On September 2, 2025, at 5:00 p.m., a multidisciplinary team led by Professor Shancheng Ren of the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), in collaboration with…

A recent study by Prof. Wai-Kay Seto (The University of Hong Kong) and Prof. Jie Li (Drum Tower Hospital, Nanjing University Medical School), published in Alimentary Pharmacology & Therapeutics, systematically reviewed the epidemiology, pathogenic mechanisms, and prognostic impact of alcohol use in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), showing that alcohol consumption significantly complicates disease progression and prognosis.

Guangzhou, China, July 26, 2025 — In a significant move to advance global efforts in the fight against hepatocellular carcinoma (HCC), the Chinese Anti-Cancer Association Liver Cancer Committee (CACA-LCC) and…

At a recent international roundtable, experts from China, Germany, and Japan shared their perspectives on the TALENT study, which evaluated the combination of TACE with atezolizumab and bevacizumab for…

Background and Objective Hepatocellular carcinoma (HCC) is among the most common malignancies globally, with a high recurrence rate after resection, especially in patients with risk factors like large tumor size,…

Editor’s Note: On the morning of March 28, the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025) officially opened. During the keynote session, APASL 2025 Scientific Committee Chair, Academician Jiahong Dong of Beijing Tsinghua Changgung Hospital, delivered a keynote speech titled “Precision Surgical Treatment of Liver Diseases” and participated in an in-depth interview with International Hepatology. In his address, Academician Dong presented IDEAL—China’s first multimodal intelligent system for precision surgical decision-making in liver diseases. He explained how IDEAL enhances the accuracy, safety, and minimally invasive nature of liver surgery, offering patients greater health benefits. Dong also emphasized the transformative role of digital technologies in surgical care, predicting their impact across clinical evaluation, surgical planning, decision-making, and data management, thus accelerating innovation in the field of hepatobiliary surgery.